Rekvina Laboratories Limited has informed the Bombay Stock Exchange about the resignation of its Non-Executive Independent Director Mr. Chetanbhai Jayantibhai Patel, effective January 29, 2026. The pharmaceutical company submitted the regulatory filing in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Director Resignation Details

Mr. Patel, who holds Director Identification Number (DIN) 06373484, tendered his resignation through a letter dated January 29, 2026. The resignation became effective from the close of business hours on the same date. Along with stepping down from his directorship, Mr. Patel has also resigned from his membership in various committees where he served as a member.

Regulatory Compliance

The company has fulfilled its disclosure obligations by providing comprehensive details as required under SEBI regulations. Company Secretary Deepak Khandelwal signed the regulatory filing, ensuring all necessary information was communicated to the stock exchange. The resignation letter explicitly states that there are no material reasons for the departure beyond the personal circumstances mentioned.

Corporate Impact

Mr. Patel's resignation affects the board composition of Rekvina Laboratories Limited, which is incorporated under CIN L24231GJ1988PLC01145. The company, headquartered in Baroda, Gujarat, operates in the pharmaceutical sector. The departing director also maintains business interests through his positions in Senpet Polymers LLP and Centurion Healthcare Pvt. Ltd.

The resignation follows standard corporate governance procedures, with the director expressing gratitude to the board and management for their support during his tenure. The company has requested the stock exchange to acknowledge receipt of the intimation and update their records accordingly.

Rekvina Laboratories Limited has appointed Jay Chintan Patel as Additional Non-Executive Independent Director during its board meeting held on January 29, 2026. The appointment was approved pursuant to the provisions of the Companies Act, 2013 and SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Appointment Details

The company provided comprehensive details regarding the new directorship appointment:

Professional Background

Jay Patel brings significant entrepreneurial and technology expertise to the board. He serves as Founder and Director of Duchas Technologies Private Limited, a DPIIT and Startup India-recognized startup. His professional focus encompasses building and scaling innovative solutions across multiple technology domains.

Patel's areas of specialization include:

• Artificial intelligence systems
• Biometric technologies
• Digital product development
• Advanced biometric systems
• Next-generation AI communication tools

Leadership Experience

The newly appointed director demonstrates extensive leadership capabilities in technology-driven environments. His experience spans strategic decision-making, product development, and organizational growth management. Patel has successfully managed cross-functional teams while guiding interns and collaborators throughout various project phases.

His leadership approach focuses on building sustainable technology-driven products with long-term global potential. The director has experience presenting to investors and stakeholders, ensuring innovation translates into practical, market-ready solutions.

Regulatory Compliance

Rekvina Laboratories confirmed full compliance with regulatory requirements for the appointment. In accordance with SEBI Letter dated June 14, 2018 and BSE Circular List/COMP/14/2018-19 dated June 20, 2018, the company verified that Jay Chintan Patel has not been debarred from holding directorship by SEBI or any other authority.

The company also disclosed that the new director maintains no relationships with existing board members, ensuring independence in his directorial capacity. The appointment follows all disclosure requirements under Regulation 30 of SEBI (LODR) Regulations, 2015 and SEBI Circular No. SEBI/HO/CFD/CFDPoD-1/CIR/2023/123 dated July 13, 2023.